Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1346

1.

Hepatitis C therapy with direct antiviral agents in patients with advanced chronic kidney disease: real-world experience of the German Hepatitis C-Registry (Deutsches Hepatitis C-Register).

Wiegand J, Buggisch P, Mauss S, Boeker KHW, Klinker H, Müller T, Günther R, Serfert Y, Manns MP, Zeuzem S, Berg T, Hinrichsen H, C-Registry GH.

Eur J Gastroenterol Hepatol. 2019 Nov;31(11):1424-1431. doi: 10.1097/MEG.0000000000001426.

PMID:
31589184
2.

Soluble immune markers in the different phases of chronic hepatitis B virus infection.

Wiegand SB, Beggel B, Wranke A, Aliabadi E, Jaroszewicz J, Xu CJ, Li Y, Manns MP, Lengauer T, Wedemeyer H, Kraft ARM, Falk CS, Cornberg M.

Sci Rep. 2019 Oct 1;9(1):14118. doi: 10.1038/s41598-019-50729-5.

3.

Hepatitis E Virus (HEV)-Specific T Cell Receptor Cross-Recognition: Implications for Immunotherapy.

Soon CF, Zhang S, Suneetha PV, Antunes DA, Manns MP, Raha S, Schultze-Florey C, Prinz I, Wedemeyer H, Sällberg Chen M, Cornberg M.

Front Immunol. 2019 Sep 4;10:2076. doi: 10.3389/fimmu.2019.02076. eCollection 2019.

4.

[Treatment strategies for acute-on-chronic liver failure].

Kabbani AR, Tergast TL, Manns MP, Maasoumy B.

Med Klin Intensivmed Notfmed. 2019 Aug 28. doi: 10.1007/s00063-019-00613-x. [Epub ahead of print] Review. German.

PMID:
31463674
5.

Multicenter Validation Study of a Diagnostic Algorithm to Detect NASH and Fibrosis in NAFLD Patients With Low NAFLD Fibrosis Score or Liver Stiffness.

Liebig S, Stoeckmann N, Geier A, Rau M, Schattenberg JM, Bahr MJ, Manns MP, Jaeckel E, Schulze-Osthoff K, Bantel H.

Clin Transl Gastroenterol. 2019 Aug;10(8):e00066. doi: 10.14309/ctg.0000000000000066.

6.

Sustained impact of nosocomial-acquired spontaneous bacterial peritonitis in different stages of decompensated liver cirrhosis.

Kimmann M, Tergast TL, Schultalbers M, Laser H, Gerbel S, Manns MP, Cornberg M, Maasoumy B.

PLoS One. 2019 Aug 2;14(8):e0220666. doi: 10.1371/journal.pone.0220666. eCollection 2019.

7.

Systemic arterial blood pressure determines the therapeutic window of non-selective beta blockers in decompensated cirrhosis.

Tergast TL, Kimmann M, Laser H, Gerbel S, Manns MP, Cornberg M, Maasoumy B.

Aliment Pharmacol Ther. 2019 Sep;50(6):696-706. doi: 10.1111/apt.15439. Epub 2019 Aug 2.

PMID:
31373713
8.

Treatment of Chronic Hepatitis C: Efficacy, Side Effects and Complications.

Sandmann L, Schulte B, Manns MP, Maasoumy B.

Visc Med. 2019 Jun;35(3):161-170. doi: 10.1159/000500963. Epub 2019 May 21. Review.

9.

The impact of proton pump inhibitors on the intestinal microbiota in chronic hepatitis C patients.

Wellhöner F, Döscher N, Tergast TL, Vital M, Plumeier I, Kahl S, Potthoff A, Manns MP, Maasoumy B, Wedemeyer H, Cornberg M, Pieper DH, Heidrich B.

Scand J Gastroenterol. 2019 Aug;54(8):1033-1041. doi: 10.1080/00365521.2019.1647280. Epub 2019 Jul 30.

PMID:
31361979
10.

Dilatation Therapy and Demographic Characteristics Significantly Influence the Amount of Propofol for Therapeutic Endoscopic Retrograde Cholangiography.

Schmidt CA, Keil C, Kirstein MM, Lehner F, Manns MP, von Hahn T, Lankisch TO, Voigtländer T.

Int J Hepatol. 2019 Jul 1;2019:4793096. doi: 10.1155/2019/4793096. eCollection 2019.

11.

Therapeutic plasma exchange in acute liver failure.

Stahl K, Hadem J, Schneider A, Manns MP, Wiesner O, Schmidt BMW, Hoeper MM, Busch M, David S.

J Clin Apher. 2019 Oct;34(5):589-597. doi: 10.1002/jca.21737. Epub 2019 Jul 26.

PMID:
31348553
12.

Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial.

Traussnigg S, Schattenberg JM, Demir M, Wiegand J, Geier A, Teuber G, Hofmann WP, Kremer AE, Spreda F, Kluwe J, Petersen J, Boettler T, Rainer F, Halilbasic E, Greinwald R, Pröls M, Manns MP, Fickert P, Trauner M; Austrian/German NAFLD-norUDCA study group.

Lancet Gastroenterol Hepatol. 2019 Oct;4(10):781-793. doi: 10.1016/S2468-1253(19)30184-0. Epub 2019 Jul 22.

PMID:
31345778
13.

Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy.

Niemann J, Woller N, Brooks J, Fleischmann-Mundt B, Martin NT, Kloos A, Knocke S, Ernst AM, Manns MP, Kubicka S, Wirth TC, Gerardy-Schahn R, Kühnel F.

Nat Commun. 2019 Jul 19;10(1):3236. doi: 10.1038/s41467-019-11137-5.

14.

Elimination of hepatitis C virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T cell responses.

Aregay A, Owusu Sekyere S, Deterding K, Port K, Dietz J, Berkowski C, Sarrazin C, Manns MP, Cornberg M, Wedemeyer H.

J Hepatol. 2019 Nov;71(5):889-899. doi: 10.1016/j.jhep.2019.06.025. Epub 2019 Jul 8.

PMID:
31295532
15.

Effects of adenovirus-induced hepatocyte damage on chronic bile duct inflammation in a sclerosing cholangitis mouse model.

Fuchs S, Bayer M, Taubert R, Manns MP, Pfeilschifter JM, Christen U, Hintermann E.

Liver Int. 2019 Jun 21. doi: 10.1111/liv.14183. [Epub ahead of print]

PMID:
31225929
16.

Defining virus-specific CD8+ TCR repertoires for therapeutic regeneration of T cells against chronic hepatitis E.

Soon CF, Behrendt P, Todt D, Manns MP, Wedemeyer H, Sällberg Chen M, Cornberg M.

J Hepatol. 2019 Oct;71(4):673-684. doi: 10.1016/j.jhep.2019.06.005. Epub 2019 Jun 14.

PMID:
31203151
17.

Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes.

Tenspolde M, Zimmermann K, Weber LC, Hapke M, Lieber M, Dywicki J, Frenzel A, Hust M, Galla M, Buitrago-Molina LE, Manns MP, Jaeckel E, Hardtke-Wolenski M.

J Autoimmun. 2019 Sep;103:102289. doi: 10.1016/j.jaut.2019.05.017. Epub 2019 Jun 5.

18.

Generation of focal mutations and large genomic deletions in the pancreas using inducible in vivo genome editing.

Mishra A, Emamgholi F, Erlangga Z, Hartleben B, Unger K, Wolff K, Teichmann U, Kessel M, Woller N, Kühnel F, Dow LE, Manns MP, Vogel A, Lowe SW, Saborowski A, Saborowski M.

Carcinogenesis. 2019 Jun 6. pii: bgz108. doi: 10.1093/carcin/bgz108. [Epub ahead of print]

PMID:
31170286
19.

Endoscopic biliary drainage in patients with cholangiocarcinoma - self-expanding metal versus polyethylene stents.

Voigtländer T, Schweitzer N, von Hahn T, Manns MP, Vogel A, Kirstein MM.

Scand J Gastroenterol. 2019 May;54(5):640-645. doi: 10.1080/00365521.2019.1614661. Epub 2019 May 24.

PMID:
31122083
20.

Chronic hepatitis delta virus infection leads to functional impairment and severe loss of MAIT cells.

Dias J, Hengst J, Parrot T, Leeansyah E, Lunemann S, Malone DFG, Hardtke S, Strauss O, Zimmer CL, Berglin L, Schirdewahn T, Ciesek S, Marquardt N, von Hahn T, Manns MP, Cornberg M, Ljunggren HG, Wedemeyer H, Sandberg JK, Björkström NK.

J Hepatol. 2019 Aug;71(2):301-312. doi: 10.1016/j.jhep.2019.04.009. Epub 2019 May 14.

PMID:
31100314
21.

Utility of viral kinetics in HCV therapy - It is not over until it is over?

Sandmann L, Manns MP, Maasoumy B.

Liver Int. 2019 May;39(5):815-817. doi: 10.1111/liv.14047. No abstract available.

PMID:
31020775
22.

Outcomes of renal dysfunction in patients with acute liver failure.

Hadem J, Kielstein JT, Manns MP, Kümpers P, Lukasz A.

United European Gastroenterol J. 2019 Apr;7(3):388-396. doi: 10.1177/2050640618817061. Epub 2018 Dec 3.

23.

A Retrospective Analysis of Nonocclusive Mesenteric Ischemia in Medical and Surgical ICU Patients: Clinical Data on Demography, Clinical Signs, and Survival.

Stahl K, Busch M, Maschke SK, Schneider A, Manns MP, Fuge J, Wiesner O, Meyer BC, Hoeper MM, Hinrichs JB, David S.

J Intensive Care Med. 2019 Mar 25:885066619837911. doi: 10.1177/0885066619837911. [Epub ahead of print]

PMID:
30909787
24.

Characterization of the Filovirus-Resistant Cell Line SH-SY5Y Reveals Redundant Role of Cell Surface Entry Factors.

Zapatero-Belinchón FJ, Dietzel E, Dolnik O, Döhner K, Costa R, Hertel B, Veselkova B, Kirui J, Klintworth A, Manns MP, Pöhlmann S, Pietschmann T, Krey T, Ciesek S, Gerold G, Sodeik B, Becker S, von Hahn T.

Viruses. 2019 Mar 19;11(3). pii: E275. doi: 10.3390/v11030275.

25.

Impact of CD4+ blood cell count and HIV viral load on treatment response with direct acting antivirals in HIV and HCV coinfected patients: insights from the German Hepatitis C-Registry.

Bischoff J, Mauss S, Cordes C, Lutz T, Scholten S, Cornberg M, Manns MP, Baumgarten A, Rockstroh JK.

HIV Clin Trials. 2018 Dec;19(6):225-234. doi: 10.1080/15284336.2018.1538193.

PMID:
30890063
26.

Murine Liver Organoids as a Genetically Flexible System to Study Liver Cancer In Vivo and In Vitro.

Saborowski A, Wolff K, Spielberg S, Beer B, Hartleben B, Erlangga Z, Becker D, Dow LE, Marhenke S, Woller N, Unger K, Schirmacher P, Manns MP, Marquardt JU, Vogel A, Saborowski M.

Hepatol Commun. 2019 Feb 5;3(3):423-436. doi: 10.1002/hep4.1312. eCollection 2019 Mar.

27.

Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial.

Wedemeyer H, Yurdaydin C, Hardtke S, Caruntu FA, Curescu MG, Yalcin K, Akarca US, Gürel S, Zeuzem S, Erhardt A, Lüth S, Papatheodoridis GV, Keskin O, Port K, Radu M, Celen MK, Idilman R, Weber K, Stift J, Wittkop U, Heidrich B, Mederacke I, von der Leyen H, Dienes HP, Cornberg M, Koch A, Manns MP; HIDIT-II study team.

Lancet Infect Dis. 2019 Mar;19(3):275-286. doi: 10.1016/S1473-3099(18)30663-7.

PMID:
30833068
28.

HCC Immune Surveillance and Antiviral Therapy of Hepatitis C Virus Infection.

Owusu Sekyere S, Schlevogt B, Mettke F, Kabbani M, Deterding K, Wirth TC, Vogel A, Manns MP, Falk CS, Cornberg M, Wedemeyer H.

Liver Cancer. 2019 Feb;8(1):41-65. doi: 10.1159/000490360. Epub 2018 Jul 18.

29.

Treatment strategies for patients with decompensated liver cirrhosis due to hepatitis C virus infection eligible for liver transplantation: real-life data from five German transplant centers.

Sandmann L, Dörge P, Wranke A, Vermehren J, Welzel TM, Berg CP, Grottenthaler JM, Weiss KH, Langel J, Sterneck M, von Wulffen M, Manns MP, Wedemeyer H, Hardtke S, von Hahn T.

Eur J Gastroenterol Hepatol. 2019 Aug;31(8):1049-1056. doi: 10.1097/MEG.0000000000001386.

PMID:
30807443
30.

Second-line chemotherapy in biliary tract cancer: Outcome and prognostic factors.

Schweitzer N, Kirstein MM, Kratzel AM, Mederacke YS, Fischer M, Manns MP, Vogel A.

Liver Int. 2019 May;39(5):914-923. doi: 10.1111/liv.14063. Epub 2019 Mar 18.

PMID:
30716200
31.

Transient increase of activated regulatory T cells early after kidney transplantation.

Mederacke YS, Vondran FW, Kollrich S, Schulde E, Schmitt R, Manns MP, Klempnauer J, Schwinzer R, Noyan F, Jaeckel E.

Sci Rep. 2019 Jan 31;9(1):1021. doi: 10.1038/s41598-018-37218-x.

32.

Treatment with metformin is associated with a prolonged survival in patients with hepatocellular carcinoma.

Schulte L, Scheiner B, Voigtländer T, Koch S, Schweitzer N, Marhenke S, Ivanyi P, Manns MP, Rodt T, Hinrichs JB, Weinmann A, Pinter M, Vogel A, Kirstein MM.

Liver Int. 2019 Apr;39(4):714-726. doi: 10.1111/liv.14048. Epub 2019 Feb 7.

PMID:
30663219
33.

[4 years of direct-acting antivirals (DAAs) in the German Hepatitis C-Registry (DHC-R)].

Hüppe D, Serfert Y, Buggisch P, Mauss S, Böker KHW, Müller T, Klinker H, Günther R, Berg T, Cornberg M, Niederau C, Sarrazin C, Simon KG, Zeuzem S, Manns MP, Wedemeyer H.

Z Gastroenterol. 2019 Jan;57(1):27-36. doi: 10.1055/a-0821-7188. Epub 2019 Jan 14. German.

PMID:
30641600
34.

Cholemic Nephropathy Causes Acute Kidney Injury and Is Accompanied by Loss of Aquaporin 2 in Collecting Ducts.

Bräsen JH, Mederacke YS, Schmitz J, Diahovets K, Khalifa A, Hartleben B, Person F, Wiech T, Steenbergen E, Großhennig A, Manns MP, Schmitt R, Mederacke I.

Hepatology. 2019 May;69(5):2107-2119. doi: 10.1002/hep.30499. Epub 2019 Mar 14.

PMID:
30633816
35.

Predniso(lo)ne Dosage and Chance of Remission in Patients With Autoimmune Hepatitis.

Pape S, Gevers TJG, Belias M, Mustafajev IF, Vrolijk JM, van Hoek B, Bouma G, van Nieuwkerk CMJ, Hartl J, Schramm C, Lohse AW, Taubert R, Jaeckel E, Manns MP, Papp M, Stickel F, Heneghan MA, Drenth JPH.

Clin Gastroenterol Hepatol. 2019 Sep;17(10):2068-2075.e2. doi: 10.1016/j.cgh.2018.12.035. Epub 2019 Jan 6.

PMID:
30625402
36.

Hepatocyte-specific suppression of microRNA-221-3p mitigates liver fibrosis.

Tsay HC, Yuan Q, Balakrishnan A, Kaiser M, Möbus S, Kozdrowska E, Farid M, Tegtmeyer PK, Borst K, Vondran FWR, Kalinke U, Kispert A, Manns MP, Ott M, Sharma AD.

J Hepatol. 2019 Apr;70(4):722-734. doi: 10.1016/j.jhep.2018.12.016. Epub 2018 Dec 22.

PMID:
30582979
37.

Role of soluble inflammatory mediators and different immune cell populations in early control of symptomatic acute hepatitis C virus infection.

Hengst J, Klein AL, Lunemann S, Deterding K, Hardtke S, Falk CS, Manns MP, Cornberg M, Schlaphoff V, Wedemeyer H.

J Viral Hepat. 2019 Apr;26(4):466-475. doi: 10.1111/jvh.13050. Epub 2019 Feb 1.

PMID:
30548086
38.

Editorial: "real world data" of AIH-time to connect!

Hupa-Breier KL, Taubert R, Jaeckel E, Manns MP.

Aliment Pharmacol Ther. 2018 Dec;48(11-12):1315-1316. doi: 10.1111/apt.15028. No abstract available.

PMID:
30488627
39.

Increased seroprevalence of HAV and parvovirus B19 in children and of HEV in adults at diagnosis of autoimmune hepatitis.

Taubert R, Diestelhorst J, Junge N, Kirstein MM, Pischke S, Vogel A, Bantel H, Baumann U, Manns MP, Wedemeyer H, Jaeckel E.

Sci Rep. 2018 Nov 28;8(1):17452. doi: 10.1038/s41598-018-35882-7.

40.

SEC14L2, a lipid-binding protein, regulates HCV replication in culture with inter- and intra-genotype variations.

Costa R, Todt D, Zapatero-Belinchón F, Schenk C, Anastasiou OE, Walker A, Hertel B, Timmer L, Bojkova D, Ruckert M, Sarrazin C, Timm J, Lohmann V, Manns MP, Steinmann E, von Hahn T, Ciesek S.

J Hepatol. 2019 Apr;70(4):603-614. doi: 10.1016/j.jhep.2018.11.012. Epub 2018 Nov 23.

PMID:
30472319
41.

Functional and immunogenic characterization of diverse HCV glycoprotein E2 variants.

Khera T, Behrendt P, Bankwitz D, Brown RJP, Todt D, Doepke M, Khan AG, Schulze K, Law J, Logan M, Hockman D, Wong JAJ, Dold L, Gonzalez-Motos V, Spengler U, Viejo-Borbolla A, Ströh LJ, Krey T, Tarr AW, Steinmann E, Manns MP, Klein F, Guzman CA, Marcotrigiano J, Houghton M, Pietschmann T.

J Hepatol. 2019 Apr;70(4):593-602. doi: 10.1016/j.jhep.2018.11.003. Epub 2018 Nov 13.

PMID:
30439392
42.

Novel therapeutic targets in autoimmune hepatitis.

Taubert R, Hupa-Breier KL, Jaeckel E, Manns MP.

J Autoimmun. 2018 Dec;95:34-46. doi: 10.1016/j.jaut.2018.10.022. Epub 2018 Nov 4. Review.

PMID:
30401504
43.

Estimation of liver fibrosis by noncommercial serum markers in comparison with transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral treatment.

Knop V, Hofmann WP, Buggisch P, Klinker H, Mauss S, Günther R, Hinrichsen H, Hüppe D, Pfeiffer-Vornkahl H, Simon KG, Berg T, Manns MP, Friedrich-Rust M; German Hepatitis C-Registry.

J Viral Hepat. 2019 Feb;26(2):224-230. doi: 10.1111/jvh.13021. Epub 2018 Nov 8.

PMID:
30315694
44.

Shear wave elastography prior to transjugular intrahepatic portosystemic shunt may predict the decrease in hepatic vein pressure gradient.

Attia D, Rodt T, Marquardt S, Hinrichs J, Meyer BC, Gebel M, Wacker F, Manns MP, Potthoff A.

Abdom Radiol (NY). 2019 Mar;44(3):1127-1134. doi: 10.1007/s00261-018-1795-6.

PMID:
30288582
45.

Long-term changes in liver elasticity in hepatitis C virus-infected patients with sustained virologic response after treatment with direct-acting antivirals.

Pietsch V, Deterding K, Attia D, Ringe KI, Heidrich B, Cornberg M, Gebel M, Manns MP, Wedemeyer H, Potthoff A.

United European Gastroenterol J. 2018 Oct;6(8):1188-1198. doi: 10.1177/2050640618786067. Epub 2018 Jun 27.

46.

Clinical characteristics of patients with liver cirrhosis and spontaneous portosystemic shunts detected by ultrasound in a tertiary care and transplantation centre.

Lipinski M, Saborowski M, Heidrich B, Attia D, Kasten P, Manns MP, Gebel M, Potthoff A.

Scand J Gastroenterol. 2018 Sep;53(9):1107-1113. doi: 10.1080/00365521.2018.1498913. Epub 2018 Sep 29.

PMID:
30270689
47.

[Biliary atresia and congenital cholestatic syndromes : Characteristics before, after and during transition].

Junge N, Dingemann J, Petersen C, Manns MP, Richter N, Klempnauer J, Baumann U, Schneider A.

Internist (Berl). 2018 Nov;59(11):1146-1156. doi: 10.1007/s00108-018-0506-2. Review. German.

PMID:
30264190
48.

Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival.

Marquardt S, Kirstein MM, Brüning R, Zeile M, Ferrucci PF, Prevoo W, Radeleff B, Trillaud H, Tselikas L, Vicente E, Wiggermann P, Manns MP, Vogel A, Wacker FK.

Eur Radiol. 2019 Apr;29(4):1882-1892. doi: 10.1007/s00330-018-5729-z. Epub 2018 Sep 25.

PMID:
30255257
49.

Association Between Type 2 Diabetes Mellitus, HbA1c and the Risk for Spontaneous Bacterial Peritonitis in Patients with Decompensated Liver Cirrhosis and Ascites.

Tergast TL, Laser H, Gerbel S, Manns MP, Cornberg M, Maasoumy B.

Clin Transl Gastroenterol. 2018 Sep 24;9(9):189. doi: 10.1038/s41424-018-0053-0.

50.

Different kinetics of liver stiffness using shear wave elastography in patients with chronic hepatitis C infection treated with interferon-free regimens.

Attia D, Deterding K, Cornberg J, Gebel MJ, Cornberg M, Manns MP, Wedemeyer H, Potthoff A.

Eur J Gastroenterol Hepatol. 2019 Jan;31(1):67-74. doi: 10.1097/MEG.0000000000001259.

PMID:
30239347

Supplemental Content

Loading ...
Support Center